SYNB8802v1 for Short Bowel Syndrome

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
PPD, part of Thermo Fisher Scientific, Austin, TX
Short Bowel Syndrome+1 More
SYNB8802v1 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Study SYNB8802-CP-002 is designed to assess safety, tolerability, and oxalate lowering, in subjects with a history of gastric bypass surgery or short-bowel syndrome. In addition, this study will explore other PD effects relative to baseline as well as predictors of efficacy and tolerability.

Eligible Conditions

  • Short Bowel Syndrome
  • Enteric Hyperoxaluria

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Short Bowel Syndrome

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 43 days

17 days
Change from baseline in 24-hour excreted UOx among SYNB8802v1-treated subjects versus those treated with placebo.
Safety and tolerability of SYNB8802v1 by assessing clinical laboratory tests
Safety and tolerability of SYNB8802v1, as assessed by measuring of vital signs
43 days
Safety and tolerability of SYNB8802v1, as assessed by AEs, clinical laboratory tests, and vital sign measurements

Trial Safety

Safety Progress

1 of 3

Other trials for Short Bowel Syndrome

Trial Design

2 Treatment Groups

SYNB8802v1
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

10 Total Participants · 2 Treatment Groups

Primary Treatment: SYNB8802v1 · Has Placebo Group · Phase < 1

SYNB8802v1
Drug
Experimental Group · 1 Intervention: SYNB8802v1 · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 43 days
Closest Location: PPD, part of Thermo Fisher Scientific · Austin, TX
Photo of Austin 1Photo of Austin 2Photo of Austin 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Short Bowel Syndrome
0 CompletedClinical Trials

Who is running the clinical trial?

SynlogicLead Sponsor
8 Previous Clinical Trials
474 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You agree to all study procedures, including fixed diet, feces, urine, and blood.
You have had a gastric bypass surgery or a short-bowel surgery.
A complete blood count with differential and chemistry panel are required.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.